Advanced Clear Cell Renal Cell Carcinoma
Oncology·MeSH: Clear-cell metastatic renal cell carcinoma
Prevalence
48.0 / 100K
Incidence
15.0 / 100K/yr
7 drugs in development·4 companies·6 clinical trials
Drug Pipeline by Phase
Phase 3(5)
Phase 2(1)
| Drug | Company |
|---|---|
| Tivozanib | Replimune Group, Inc. (REPL) |
Phase 1(1)
| Drug | Company |
|---|---|
| AB521 | EXELIXIS, INC. (EXEL) |
Compare drugs
Frequently asked questions
How many drugs are in development for Advanced Clear Cell Renal Cell Carcinoma?
BioSniper tracks 7 drugs in development for Advanced Clear Cell Renal Cell Carcinoma across 4 companies.
How many clinical trials target Advanced Clear Cell Renal Cell Carcinoma?
There are 6 clinical trials targeting Advanced Clear Cell Renal Cell Carcinoma tracked by BioSniper.
What is the prevalence of Advanced Clear Cell Renal Cell Carcinoma?
The estimated prevalence of Advanced Clear Cell Renal Cell Carcinoma is approximately 48.0 per 100,000 population.
Deep-dive into Advanced Clear Cell Renal Cell Carcinoma
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis